The negative regulation of red cell mass by neocytolysis: Physiologic and pathophysiologic manifestations

Cellular Physiology and Biochemistry

Volumn 15, Issue 6, 2005, Pages 245-250

  Rice, Lawrence ^a,b   Alfrey, Clarence P ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MS 902 Main ^*  (United States)

Author keywords

Blood Doping; Erythropoiesis; Erythropoietin; Hemolytic Anemia; Neocytolysis; Polycythemia; Red Cell Mass; Spaceflight Anemia

Indexed keywords

BILIRUBIN; CADHERIN; CHONDROITIN SULFATE; CYTOKINE; ERYTHROPOIETIN; FERRITIN; GLYCOPHORIN A; HEMOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 4; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATIDYLSERINE; PORPHYRIN; POTASSIUM; UNCLASSIFIED DRUG; UROBILINOGEN; VON WILLEBRAND FACTOR;

ALTITUDE; ANEMIA; ASTRONOMY; ATHLETE; BLOOD VOLUME; CELL POPULATION; COSMONAUT; CYTOLYSIS; DOPING; ENDOTHELIUM CELL; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; ERYTHROPOIESIS; GRAVITY; HEMATOCRIT; HEMOLYTIC ANEMIA; HUMAN; HYPERKALEMIA; HYPOXIA; KIDNEY DISEASE; MICROGRAVITY; MOLECULAR MECHANICS; NEWBORN JAUNDICE; OXYGEN THERAPY; PATHOPHYSIOLOGY; PHAGOCYTE; PHYSIOLOGY; POLYCYTHEMIA; PRECIPITATION; PRIORITY JOURNAL; RETICULOCYTE COUNT; RETICULOENDOTHELIAL SYSTEM; REVIEW; SEA LEVEL; SIGNAL TRANSDUCTION; THEORETICAL MODEL; UTERUS;

EID: 22544478796     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087234     Document Type: Review

References (25)

1. Alfrey CP, Rice L, Udden M, Driscoll T: Neocytolysis: A physiologic down-regulator of red blood cell mass. Lancet 1997;349:1389.
2. Alfrey CP, Udden MU, Leach-Huntoon C, Driscoll T, Pickett MH: Control of the red blood cell mass in spaceflight. J Appl Physiol 1996;81:98.
3. Rice L, Ruiz W, Driscoll T, Whitley C, Tapia R, Hachey DL, Gonzales G, Alfrey CP: Neocytolysis on descent from altitude: A newly recognized mechanism for the control of red cell mass. Ann Intern Med 2001; 134:652-6.
4. Rice L, Driscoll T, Whitley C, Hachey DL, Suki W, Alfrey CP: Neocytolysis contributes to the anemia of renal disease. Amer J Kid Dis 1999;33:59-62.
5. Groopman J: Medicine on Mars. The New Yorker 2000, pp. 36-41.
6. Udden MM, Driscoll TB, Pickett MH, Leach-Huntoon CS, Alfrey CP: Decreased production of red blood cells in human subjects exposed to microgravity. J Lab Clin Med 1995;125:442-449.
7. Koury MJ, Bondurant MC: Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990;248:378-381.
8. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F: Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and simulates neovascularization in vivo. Blood 1999;93:2627-2636.
9. Trial J, Rice L, Alfrey CP: Erythropoietin withdrawal alters interactions between young red cells, splenic endothelial cells, and macrophages: an in vitro model of neocytolysis. J Invest Med 2001;49:335-345.
10. Stohlman F Jr: Observations on the kinetics of red cell proliferation; in Stohlman F Jr (ed): The kinetics of cellular proliferation. NY, Grune & Stratton, 1959, pp 318-329.
11. Merino CF: Studies of blood formation and destruction in the polycythemia of high altitude. Blood 1950;5:1-31.
12. Huff RL, Lawrence JH, Siri WE, Wasserman LR, Hennessy TG: Effects of changes in altitude on hematopoietic activity. Medicine 1951;30:197-217.
13. Pace N, Meyer LB, Vaughan BE: Erythrolysis on return of altitude acclimatized individuals to sea level. J Appl Physiol 1952;171:465-470.
14. Adamson JW, Eschbach J, Finch C: The kidney and erythropoiesis. Blood 1968;44:725-733.
15. Eschbach JW: The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-148.
16. Polenakovic M, Sikole A: Is erythropoietin a survival factor for red blood cells? J Amer Soc Nephrol 1996;7:1178-1182.
17. Usberti M, Bove S, Gerardi G, Micheli AM, Faustini M, Ruggeri G: Neocytolysis in hemodialyzed patients: a recent recognized action of erythropoietin. Different effects of darbepoietin-alpha and erythropoietin-beta. Submitted for publication.
18. Besarab A: Optimizing epoietin therapy in end-stage renal disease: the case for subcutaneous administration. Am J Kidney Dis 1993;22:13-22.
19. Kaufman JS, Domenic JR, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA: Subcutaneous compared with intravenous Epoietin in patients receiving hemodialysis. N Engl J Med 1998;339:578-583.
20. Harris BA Jr, Epstein PE: Out of thin air: the evolving enigma of erythropoietin and neocytolysis. Ann Intern Med 2001;134:710-712.
21. Leigh-Smith S: Blood boosting. Brit J Sports Med 2004;38:99-101.
22. Bergland B, Girgegard G, Wide L, Philstedt P: Effects of blood transfusions on some haematological variables in endurance athletes. Med Sci Sports Exerc 1989;21:637-642.
23. Crosby WH: Splenic remodeling of red cell surfaces. Blood 1977;50:643-645.
24. Trial J, Rice L: Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interface. Curr Pharmaceutical Design 2004;10:183-190.
25. Rice L, Alfrey CP: Modulation of red cell mass by neocytolysis in space and on Earth. Pflugers Arch Eur J Physiol 2000;441:R91-94.